Condition: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Sponsor: Fudan University
Extranodal NK/T-cell lymphoma, nasal type (NKTCL) is a common malignant tumor in East Asian populations, often starting in the nasal cavity and spreading to other organs. Associated with EBV infection, NKTCL is aggressive. Early-stage patients typically receive chemo and radiotherapy, with promising outcomes. Recent studies show the potential of immune checkpoint inhibitors in NKTCL treatment. However, optimal treatment sequencing and efficacy remain unclear. This study aims to compare three strategies: (A) Pegaspargase with Sintilimab and radiotherapy; (B) chemo then radiotherapy (PGemOx); (C) sandwich chemoradiotherapy (GELAD). The goal is to identify the best treatment based on 24-month progression-free survival.
This description comes directly from the study's public registry record.
Rong Tao, MD · 8621-64175590 · rtao@shca.org.cn
Chuanxu Liu, MD · 021-64175590 · liuchuanxu@shca.org.cn
Always discuss trial participation with your own doctor first.
| Cancer Hospital of Fujian Province | Fuzhou, Fujian, China | Recruiting |
| Nantong Cancer Hospital | Nantong, Jiangsu, China | Recruiting |
| Shanghai Eye Ear Nose and Throat Hospital，Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
| People's Hospital of Ningbo University | Ningbo, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06314334